CJC-1295 With DAC vs Without DAC: Research Comparison

CJC-1295 with DAC and products labeled “CJC-1295 without DAC” are often placed side by side, but the names should not be treated as a minor packaging distinction. The affinity modification changes how the named research construct interacts with albumin, while the no-DAC label still needs an exact sequence and documentation context.

CJC-1295 DAC vs no DAC at a glance

What DAC means in the original CJC-1295 research

The CJC-1295 construct described by Jetté and colleagues was based on human growth-hormone-releasing factor residues 1–29. The researchers introduced substitutions intended to improve stability and added a maleimido-containing lysine derivative. That reactive feature was designed to form a covalent bioconjugate with the free thiol at cysteine 34 of serum albumin.

In that study, albumin binding was not a decorative label term. It was part of the construct’s design and was investigated using cultured rat pituitary cells, rat experiments, pharmacokinetic analysis, and immunoreactive detection associated with serum albumin. The article identified the selected construct as CJC-1295.

Why “without DAC” requires more identity context

Commercial catalogs often use “CJC-1295 without DAC,” “CJC no DAC,” or another related shorthand. Those phrases signal the absence of the albumin-binding affinity modification, but a negative description does not fully define a molecule. Researchers should still verify the stated sequence, substitutions, terminal chemistry, batch identifier, and analytical documentation.

This is especially important when applying literature. A result obtained with the affinity-modified CJC-1295 construct should not be assigned automatically to a differently labeled no-DAC material. Closely related growth-hormone-releasing-factor analogues can share a receptor research context while differing in modification, stability, metabolism, or analytical detection.

The literature itself reflects naming complexity

A later primary analytical study investigated in-vitro metabolism and detection of several synthetic growth-hormone-releasing-hormone analogues. Its analyte list distinguished CJC-1295 from CJC-1295 with drug affinity complex. That wording differs from some earlier CJC-1295 literature and from common catalog usage, which is precisely why an exact material definition matters more than a nickname.

When two papers use similar names, compare the methods section, sequence, modification, reference standard, mass transitions, and supplier information before combining their conclusions. A search-result title or catalog heading is not enough evidence that the same test article was used.

What the long-acting CJC-1295 study establishes

Teichman and colleagues conducted randomized, placebo-controlled trials of a long-acting CJC-1295 analogue and reported sustained pharmacokinetic and pharmacodynamic observations for the studied construct. Those data are an important literature anchor for the affinity-modified material. They are not a universal specification for every product that includes “CJC” or “no DAC” in its name.

Study results also do not verify a commercial vial. Product identity, labeled amount, batch documentation, storage history, and the analytical method remain separate evidence layers.

The CJC-1295 and ipamorelin blend is a third format

ELMNTPEP also lists CJC-1295 w/o DAC + Ipamorelin — 5mg / 5mg. That is a labeled two-component blend, not a third strength of the individual CJC product. Its product title states the amount attributed to each named component.

A blend name does not establish synergy, stability after combination, or equivalence to the two materials studied separately. A comparison involving the blend needs component-aware controls and an analytical method appropriate to both named materials.

Eight fields to compare before ordering

Documentation and handling complete the comparison

The literature establishes research context; product documentation addresses the supplied material. Review compound identity, batch number, analytical method, result, specification, date, and report authorization using the peptide testing documentation guide. Testing documentation is available. Certificates of analysis will be posted to the site as they become available.

After receipt, preserve the comparison with a traceable record of the label, batch, arrival condition, storage state, opening, preparation, aliquots, and any excursion. The research peptide storage and handling checklist provides a general laboratory framework without imposing one unsupported condition across different materials.

Primary research references

• Jetté et al. (2005) described hGRF(1-29)-albumin bioconjugates and identified CJC-1295 as a long-lasting albumin-binding analogue.
• Teichman et al. (2006) investigated the pharmacokinetic and pharmacodynamic profile of the long-acting CJC-1295 construct in controlled trials.
• Thomas et al. (2022) studied the in-vitro metabolism and mass-spectrometric detection of several GHRH analogues, distinguishing CJC-related analytes by modification.

Explore every ELMNTPEP research comparison →

Research use notice: This article provides educational catalog and literature context. It does not provide medical, dosing, administration, performance, or therapeutic guidance. ELMNTPEP products are intended for laboratory research use only and are not for human or veterinary consumption.